Impact of Respiratory Syncytial Virus (RSV) on adult haematology oncology patients
Authors:
- F. FarinaFFF. Farina
- V. FerlaVFV. Ferla
Open Access
- 20 November 2024
- journal article
- letter
- Published by Elsevier in Journal of Infection
- Vol. 89 (6) , 106347
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- American Society of Transplantation and Cellular Therapy Series: #7 - Management of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant RecipientsTransplantation and Cellular Therapy, 2023
- Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older AdultsNew England Journal of Medicine, 2023
- Viral Lineages in the 2022 RSV Surge in the United StatesNew England Journal of Medicine, 2023
- Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older AdultsNew England Journal of Medicine, 2023
- Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational studyThe Lancet Infectious Diseases, 2022
- COVID-19 in recipients of allogeneic stem cell transplantation: favorable outcomeBone Marrow Transplantation, 2021
- Community-Acquired Respiratory Viruses in Transplant Patients: Diversity, Impact, Unmet Clinical NeedsClinical Microbiology Reviews, 2019
- Respiratory syncytial virus (RSV): a scourge from infancy to old ageThorax, 2019
- Respiratory syncytial virus infection in elderly adultsMedecine Et Maladies Infectieuses, 2018
- Detection and Control of a Nosocomial Respiratory Syncytial Virus Outbreak in a Stem Cell Transplantation Unit: The Role of PalivizumabTransplantation and Cellular Therapy, 2010